Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

Next Previous
Search
Trial Profile

A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UB 612 (Primary) ; AZD 1222; BBIBP CorV; Tozinameran
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Vaxxinity

    • Most Recent Events

    • 13 Nov 2023 According to a Vaxxinity media release, today announced that scientists and executives will present data from this phase3 trial in upcoming medical and investor conference-Vaccines Summit-2023 on 14 Nov 2023.
    • 02 Mar 2023 According to a Vaxxinity media release, company and its scientists and executives will present results of this trial at upcoming scientific and medical conferences in March, on 20 Mar 2023 at 11:30 am EDT at Cambridge, Mass. (Kimpton Marlowe Hotel).
    • 02 Dec 2022 Results published in a Vaxxinity media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top